It has been analyzed recent advances in the diagnosis and treatment of primary autoimmune neuropathies—a group of rare and debilitating disorders of the peripheral nervous system that includes Guill...
Read moreLos resultados mostraron que, ya desde el inicio, quienes acabaron desarrollando ERC tenían niveles más altos de marcadores inflamatorios (IL-6, IL-1β o TNFα) y de daño oxidativo (malondialdehíd...
Read moreLa Unidad de Deterioro Cognitivo del centro hospitalario participa en tres ensayos clínicos y atiende a más de 3.500 pacientes cada año que padecen esta enfermedad neurodegenerativa
Read moreADmit Therapeutics has announced the publication of a blood biomarker in the journal iScience. The study details the fundamental research that led to the development of the Test MAP-AD®, a prognostic...
Read moreThe MAP-AD® Test is a qualitative in vitro diagnostic (IVD) blood test for the prognosis of the progression from Mild Cognitive Impairment to AD dementia in adult patients between 55 and 85 years old...
Read moreThe study demonstrates how the MAF Test®, which stratifies early-stage breast cancer patients by MAF gene status to guide adjuvant bisphosphonate therapy, delivers meaningful economic value across mu...
Read moreEl test sanguíneo MAP-AD® de la compañía ADmit Therapeutics, spin-off del IDIBELL, con el Hospital de Bellvitge como centro coordinador clínico, logra un hito regulatorio con el marcado CE y abre...
Read moreLa aprobación de nuevos medicamentos con anticuerpos para la enfermedad de Alzheimer –lecanemab y donanemab– y de pruebas diagnósticas en sangre marcan el inicio de una nueva era en el diagnóst...
Read moreThe KIMA genomic signature identifies patients with HR+/HER2– breast cancer who have a lower response to CDK4/6 inhibitors, enabling more personalized treatments
Read moreThe research has been carried out in conjunction with Stanford University and has enabled designing a screening system to identify extremely selective peptides with therapeutic potential that minimize...
Read moreEste biomarcador permite detectar la presencia de depósitos de beta amiloide, patología clave en el desarrollo de la enfermedad, en personas sin deterioro cognitivo
Read moreThe study, published in Molecular Oncology, reveals that the gene TCF19 plays a critical role in prostate cancer progression, tumor growth, and metastatic spread, highlighting its potential as a progn...
Read more